Drug Monograph
Gentamicin
gentamicin sulfate — aminoglycoside antibacterial
Pharmacokinetic Profile
Half-Life
2–3 h (normal renal function)
Metabolism
None — excreted unchanged
Protein Binding
0–30% (low)
Bioavailability
100% (IV/IM); negligible oral
Volume of Distribution
~0.25 L/kg (extracellular fluid)
Clinical Information
Drug Class
Aminoglycoside
Available Forms
40 mg/mL vials; premixed 60, 80, 100 mg in NS
Route
IV infusion (30–60 min) or IM
Renal Adjustment
Required — dose/interval by CrCl & levels
Hepatic Adjustment
None required
Pregnancy
May cause fetal harm — irreversible ototoxicity reported
Lactation
Excreted in milk; low oral absorption limits infant risk
Schedule
Prescription only (not scheduled)
Generic Available
Yes
Therapeutic Index
Narrow — TDM mandatory
Black Box Warning
Yes — Nephrotoxicity, Ototoxicity, Neuromuscular Blockade
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Bacterial septicaemia | Adults, paediatrics, neonates | Monotherapy or combination | FDA Approved |
| Serious CNS infections (meningitis) | Adults, paediatrics, neonates | Combination (+ intrathecal if needed) | FDA Approved |
| Complicated urinary tract infections | Adults, paediatrics | Monotherapy or combination | FDA Approved |
| Respiratory tract infections | Adults, paediatrics | Combination (usually + beta-lactam) | FDA Approved |
| Intra-abdominal infections (peritonitis) | Adults, paediatrics | Combination | FDA Approved |
| Skin, bone, soft tissue infections (incl. burns) | Adults, paediatrics | Monotherapy or combination | FDA Approved |
Gentamicin provides concentration-dependent bactericidal activity against most aerobic gram-negative bacilli, including Pseudomonas aeruginosa, E. coli, Klebsiella, Enterobacter, Serratia, Citrobacter, and Proteus species, as well as Staphylococcus species. It is not effective against most streptococci, enterococci (when used alone), or anaerobes. When combined with cell-wall-active agents such as penicillins or vancomycin, gentamicin demonstrates synergistic bactericidal activity against enterococci and selected staphylococci.
Off-Label / Synergy Uses
Infective endocarditis (enterococcal or streptococcal) — synergy with beta-lactam or vancomycin: Widely recommended in AHA/IDSA guidelines for native and prosthetic valve endocarditis caused by enterococci and viridans streptococci. Used at low “synergy” doses (1 mg/kg q8h). Evidence quality: High.
Intra-amniotic infection (chorioamnionitis) — adjunctive to ampicillin: Standard regimen in obstetric practice. Evidence quality: High.
Surgical prophylaxis (GI/GU procedures) — in penicillin-allergic patients: Used in combination with vancomycin for endocarditis prophylaxis in high-risk patients undergoing certain procedures (per older AHA guidelines; now less commonly recommended). Evidence quality: Moderate.
Dosing
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Serious gram-negative infection — extended-interval (once-daily) dosing | 5–7 mg/kg IV q24h | Guided by Hartford nomogram | 7 mg/kg/dose | Preferred in most adults with normal renal function; use IBW or adjusted BW in obesity Draw random level at 6–14 h post-dose; plot on nomogram to determine interval (q24, q36, or q48h) |
| Serious gram-negative infection — traditional (multiple-daily) dosing | 1–1.7 mg/kg IV q8h | Adjusted by TDM | 5 mg/kg/day | 3 mg/kg/day for serious infections; up to 5 mg/kg/day for life-threatening infections, reduced to 3 mg/kg/day as soon as clinically indicated (FDA PI). Target peak 4–6 µg/mL (at 1 mg/kg dose), trough <2 µg/mL Use for patients ineligible for extended-interval dosing (burns, endocarditis, pregnancy, ascites, CrCl <20 mL/min) |
| Enterococcal / streptococcal endocarditis — synergy with beta-lactam or vancomycin | 1 mg/kg IV q8h | Adjusted by levels | 3 mg/kg/day | Target peak 3–5 µg/mL, trough <1 µg/mL Duration: 2 weeks (native valve streptococcal) to 4–6 weeks (enterococcal); per AHA/IDSA guidelines |
| Urinary tract infection — uncomplicated, susceptible organism | 1.5 mg/kg IV/IM q8h | Adjusted by levels/renal function | 5 mg/kg/day | Reserve for resistant organisms only FDA PI: aminoglycosides not indicated for uncomplicated initial UTI unless organism susceptible only to aminoglycosides |
| Renal impairment — any indication | Individualise | Extend interval ± reduce dose based on CrCl and serum levels | Per TDM | Serum creatinine and CrCl guide dose; half-life prolonged proportionally to renal impairment Removed by haemodialysis (supplement post-dialysis); poorly removed by peritoneal dialysis |
| Obesity (BMI ≥30) — weight-based dosing adjustment | Use adjusted body weight: ABW = IBW + 0.4 × (TBW − IBW). Do not use total body weight, as gentamicin distributes primarily in extracellular fluid and does not penetrate adipose tissue proportionally. Applies to both extended-interval and traditional dosing approaches | |||
Paediatric & Neonatal Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Neonatal sepsis (≤7 days, ≥35 wks GA) | 4–5 mg/kg IV q24h | Guided by levels | 5 mg/kg/dose | Extended-interval preferred in current practice; target peak 5–12 µg/mL, trough <1 µg/mL FDA PI alternative: 2.5 mg/kg q8h (7.5 mg/kg/day traditional dosing). Adjust interval by GA and postnatal age |
| Neonatal sepsis (≤7 days, <35 wks GA) | 4–5 mg/kg IV q36–48h | Guided by levels | 5 mg/kg/dose | Premature infants have reduced renal clearance FDA PI alternative: 2.5 mg/kg q12h (5 mg/kg/day traditional dosing). Combine with ampicillin for empiric coverage of early-onset neonatal sepsis |
| Children (>1 month) — serious infection | 2–2.5 mg/kg IV q8h | Adjusted by levels | 7.5 mg/kg/day | Paediatric FDA PI dosing; extended-interval (5–7.5 mg/kg q24h) also used in practice Duration 7–10 days; monitor renal function and levels closely |
Clinical Pearl: Therapeutic Drug Monitoring (TDM)
Gentamicin has a narrow therapeutic index and TDM is essential for all patients. For extended-interval dosing, a single random level drawn 6–14 hours after the first dose is plotted on the Hartford nomogram to determine the dosing interval. For traditional dosing, measure peak (30 minutes after end of infusion; FDA PI target 4–6 µg/mL at 1 mg/kg dose; clinical targets of 6–8 µg/mL may be used for life-threatening infections at higher doses) and trough (just before next dose; target <2 µg/mL). For synergy dosing, target peak 3–5 µg/mL and trough <1 µg/mL. Peaks >12 µg/mL and troughs >2 µg/mL are associated with increased toxicity risk (FDA PI).
Pharmacology
Mechanism of Action
Gentamicin is a bactericidal aminoglycoside that irreversibly binds to the 30S ribosomal subunit of susceptible bacteria. This binding causes misreading of the mRNA template and inhibition of translocation, disrupting protein synthesis and leading to cell death. Unlike purely bacteriostatic protein-synthesis inhibitors, aminoglycosides exhibit concentration-dependent killing: higher peak concentrations relative to the minimum inhibitory concentration (Cmax:MIC ratio) produce more rapid and complete bacterial killing. Gentamicin also demonstrates a clinically useful post-antibiotic effect (PAE) of 1–3 hours against gram-negative organisms, allowing extended dosing intervals despite serum levels falling below the MIC between doses. This pharmacodynamic profile underpins the rationale for extended-interval (once-daily) dosing strategies.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Negligible oral bioavailability; 100% bioavailability via IV/IM; Tmax ~30–60 min (IM); at 1 mg/kg IM, peak serum levels reach ~4 µg/mL | Must be given parenterally; peak levels proportional to dose (roughly Cmax ≈ 4 × dose in mg/kg) |
| Distribution | Vd ~0.25 L/kg; distributes into extracellular fluid; renal cortex concentrations up to 8× serum; poor CNS penetration (dependent on meningeal inflammation); crosses placenta; minimal biliary excretion | Vd may be increased in burns, ascites, sepsis (requiring higher doses); low CSF levels may necessitate intrathecal administration for CNS infections |
| Metabolism | Not metabolised; excreted as unchanged drug | No hepatic dose adjustment needed; no CYP450 interactions |
| Elimination | t½ 2–3 h (normal renal function); ≥70% recovered unchanged in urine within 24 h via glomerular filtration; renal clearance approximates CrCl; removable by haemodialysis; poorly removed by peritoneal dialysis | Half-life directly proportional to renal impairment — may exceed 24–48 h in severe renal failure; supplement dose after haemodialysis sessions; small amounts retained in renal cortex for weeks after discontinuation (tissue accumulation basis for nephrotoxicity) |
Side Effects
≥10%
Very Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nephrotoxicity (elevated BUN/SCr, proteinuria, casts, oliguria) | 7–15% | Risk increases with higher doses, prolonged therapy (>10 days), pre-existing renal impairment, dehydration, and concurrent nephrotoxins. Generally reversible with early detection and drug discontinuation (FDA PI) |
| Ototoxicity (auditory and/or vestibular) | 2–14% | Cochleotoxicity (hearing loss) ranges from 2–14% depending on monitoring criteria; vestibular toxicity in ~15% of aminoglycoside-treated patients. High-frequency loss occurs first. Usually irreversible. Risk elevated in patients with MT-RNR1 mitochondrial DNA variants (FDA PI) |
1–10%
Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Hypomagnesaemia | ~5–10% | Aminoglycoside-induced renal magnesium wasting; may manifest as tetany, weakness, Chvostek sign. Monitor and replace (FDA PI) |
| Elevated transaminases (SGOT/SGPT) | 1–5% | Isolated laboratory finding; usually transient and not associated with hepatic injury (FDA PI) |
| Eosinophilia | 1–3% | Generally asymptomatic; monitor CBC periodically (FDA PI) |
| Anaemia / leukopenia | 1–3% | Infrequent haematological changes; usually reversible (FDA PI) |
| Injection site pain | 1–2% | Rare; subcutaneous atrophy at injection site also reported (FDA PI) |
| Hypokalaemia / hypocalcaemia | 1–5% | Related to renal electrolyte wasting; may contribute to neuromuscular symptoms (FDA PI) |
Serious
Serious Adverse Effects (Regardless of Frequency)
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Irreversible sensorineural hearing loss | 2–14% | Days to weeks; may manifest after therapy ends | Baseline and serial audiometry in high-risk patients; discontinue at first sign of hearing changes; consider MT-RNR1 variant testing if maternal history of aminoglycoside ototoxicity |
| Vestibulotoxicity (vertigo, ataxia, nystagmus) | ~15% (class effect) | Days to weeks | Assess vestibular function; discontinue or adjust dose; deficit may be permanent |
| Acute kidney injury (oliguric or non-oliguric) | 7–15% | 3–7 days into therapy | Monitor SCr daily; hold dose if rising >0.5 mg/dL above baseline; ensure adequate hydration; generally reversible if detected early |
| Neuromuscular blockade / respiratory paralysis | Rare | During or shortly after infusion/irrigation | Administer IV calcium; mechanical ventilation if required; avoid in myasthenia gravis patients; risk potentiated by NMBAs and anaesthetics |
| Fanconi-like syndrome (amino-aciduria, metabolic acidosis) | Rare | Prolonged therapy | Monitor urinalysis and electrolytes; discontinue if tubular dysfunction develops |
| Anaphylaxis / allergic reaction (contains sulfites) | Rare | During or shortly after administration | Discontinue immediately; standard anaphylaxis management; note formulation contains sodium metabisulfite |
Discontinuation
Discontinuation Rates
Primary Reasons for Discontinuation
Nephrotoxicity & Ototoxicity
Key point: The FDA PI does not provide pooled discontinuation rates. Discontinuation is typically driven by rising creatinine, detection of hearing changes, or completion of the planned 7–10 day course. Extended therapy beyond 10 days significantly increases toxicity risk.
Duration Guideline
7–10 days
FDA PI recommendation: Usual treatment is 7–10 days. Longer courses may be needed for complicated infections but require intensified monitoring of renal, auditory, and vestibular function.
Managing Nephrotoxicity
Aminoglycoside nephrotoxicity results from drug accumulation in proximal tubular cells, leading to tubular necrosis. Risk factors include prolonged courses, elevated trough levels (>2 µg/mL), concurrent nephrotoxins (vancomycin, amphotericin B, NSAIDs, contrast dye), advanced age, volume depletion, and pre-existing renal disease. Extended-interval dosing may reduce nephrotoxicity by allowing a “drug-free interval” that limits proximal tubule accumulation. Maintaining adequate hydration and monitoring daily serum creatinine during the first week of therapy are essential preventive measures.
Drug Interactions
Gentamicin is not metabolised by cytochrome P450 enzymes and has minimal protein binding, so pharmacokinetic interactions via CYP or displacement mechanisms are essentially absent. The clinically significant interactions are pharmacodynamic (additive toxicity) and relate to concurrent use of other nephrotoxic or ototoxic agents, neuromuscular blocking drugs, and in vitro inactivation by penicillins.
MajorVancomycin
MechanismAdditive nephrotoxicity; both agents cause tubular damage via distinct pathways
EffectSignificantly increased risk of acute kidney injury when combined
ManagementMonitor renal function daily; minimise overlap duration; use extended-interval gentamicin dosing where possible to reduce cumulative exposure
FDA PI / Clinical PracticeMajorLoop Diuretics (Furosemide, Ethacrynic Acid)
MechanismIndependent ototoxic potential of loop diuretics; IV diuretics may alter aminoglycoside tissue concentrations
EffectEnhanced risk of irreversible ototoxicity
ManagementAvoid concurrent use when possible, especially IV ethacrynic acid; if unavoidable, monitor hearing closely and avoid bolus IV diuretic dosing
FDA PI (Boxed Warning)MajorNeuromuscular Blocking Agents (Succinylcholine, Tubocurarine)
MechanismAminoglycosides have intrinsic curare-like neuromuscular blocking activity that potentiates NMBAs
EffectProlonged respiratory depression and neuromuscular blockade
ManagementUse with extreme caution in operative settings; have IV calcium available to reverse blockade; avoid in myasthenia gravis
FDA PIMajorAmphotericin B / Cisplatin
MechanismAdditive nephrotoxicity (both), additive ototoxicity (cisplatin)
EffectSubstantially increased renal and auditory damage
ManagementAvoid concurrent use if alternatives exist; if essential, intensify renal and auditory monitoring
FDA PI (Boxed Warning)ModeratePenicillins (Carbenicillin, Piperacillin)
MechanismIn vitro inactivation of gentamicin by beta-lactam ring opening; clinically relevant mainly in renal failure where both drugs accumulate
EffectReduced gentamicin serum levels, decreased half-life; may cause subtherapeutic aminoglycoside concentrations
ManagementNever mix in the same IV line or syringe; in renal failure, monitor gentamicin levels more frequently; note that therapeutic synergy (separate administration) remains beneficial
FDA PIModerateCephalosporins
MechanismAdditive nephrotoxic potential; reported with cephaloridine and older cephalosporins
EffectIncreased risk of nephrotoxicity
ManagementMonitor renal function; combination is frequently used clinically with acceptable safety when TDM and hydration are maintained
FDA PIMonitoring
-
Serum Drug Levels (TDM)
Before 3rd dose (traditional) or 6–14 h after 1st dose (extended-interval)
Routine Traditional: peak 4–6 µg/mL at standard dose (30 min post-infusion; up to 8 µg/mL at higher doses for life-threatening infections), trough <2 µg/mL. Synergy: peak 3–5 µg/mL, trough <1 µg/mL. Extended-interval: random level plotted on Hartford nomogram. Peaks >12 and troughs >2 µg/mL increase toxicity risk (FDA PI). Repeat at least twice weekly during therapy. -
Renal Function (BUN, SCr, CrCl)
Baseline, then daily for first week; at least twice weekly thereafter
Routine Rising creatinine ≥0.5 mg/dL above baseline or declining urine output warrants dose adjustment or discontinuation. CrCl correlates with gentamicin half-life and guides dosing interval. -
Auditory Function
Baseline audiometry; serial testing if therapy >2 weeks or high-risk
Trigger-based High-frequency hearing loss occurs first and may be initially subclinical. Patients with pre-existing hearing impairment, concurrent ototoxins, MT-RNR1 variants, or prolonged courses require serial audiometry. Tinnitus or subjective hearing changes mandate reassessment. -
Vestibular Function
Assess clinically throughout therapy
Routine Monitor for dizziness, vertigo, nystagmus, and ataxia. Vestibular damage may occur without concurrent cochlear damage. -
Electrolytes (Mg, Ca, K)
Baseline, then twice weekly
Routine Aminoglycoside-induced renal wasting of magnesium, calcium, and potassium. Hypomagnesaemia can cause tetany, weakness, and cardiac arrhythmias. Replace aggressively. -
Urinalysis
Baseline, then periodically
Routine Examine for proteinuria, casts, cells, and decreased specific gravity as early markers of tubular injury before creatinine rises. -
Neuromuscular Function
Continuous in operative/ICU settings
Trigger-based Particularly in patients receiving NMBAs, anaesthetics, or with neuromuscular disorders (myasthenia gravis). Have IV calcium available for reversal.
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to gentamicin or any aminoglycoside — cross-sensitivity exists across the class (FDA PI).
Relative Contraindications (Specialist Input Recommended)
- Pre-existing significant renal impairment — dramatically increased risk of nephrotoxicity and prolonged half-life; if used, requires intensified TDM and careful dose individualisation.
- Pre-existing auditory or vestibular impairment — increased ototoxicity risk; baseline audiometry essential before initiating therapy.
- Known MT-RNR1 mitochondrial DNA variants (m.1555A>G) — greatly increased susceptibility to aminoglycoside-induced permanent hearing loss, even at therapeutic levels. Consider alternative antibiotics unless no safe alternative exists (FDA PI).
- Pregnancy — aminoglycosides cross the placenta; irreversible bilateral congenital deafness reported with streptomycin. Use only when benefit clearly outweighs risk and no alternative exists.
- Myasthenia gravis or other neuromuscular disorders — aminoglycosides may precipitate or worsen neuromuscular blockade and respiratory depression.
Use with Caution
- Elderly patients — may have reduced renal function not reflected by serum creatinine alone; use CrCl-based dosing.
- Dehydration or volume depletion — increases nephrotoxicity risk; ensure adequate hydration before and during therapy.
- Concurrent nephrotoxic or ototoxic agents — additive toxicity with vancomycin, amphotericin B, cisplatin, loop diuretics, and NSAIDs.
- Extensive burns — altered pharmacokinetics with increased Vd and faster clearance; may require higher and/or more frequent dosing guided by TDM.
- Obesity — use adjusted body weight (ABW = IBW + 0.4[TBW − IBW]); do not dose on total body weight.
- Critically ill / septic patients — altered Vd and clearance; higher loading doses may be needed with subsequent TDM-guided adjustment.
FDA Boxed Warning
Nephrotoxicity, Ototoxicity, and Neuromuscular Blockade
Aminoglycosides, including gentamicin, are potentially nephrotoxic and ototoxic. Ototoxicity (both vestibular and auditory) may be irreversible and may manifest after completion of therapy. Renal and eighth cranial nerve function should be closely monitored. Serum concentrations should be monitored to avoid prolonged peak levels above 12 µg/mL and trough levels above 2 µg/mL. Concurrent or sequential use of other nephrotoxic and/or ototoxic agents (including other aminoglycosides, cisplatin, polymyxins, vancomycin) should be avoided. Concurrent use of potent diuretics (ethacrynic acid, furosemide) should be avoided as diuretics may enhance aminoglycoside toxicity. Aminoglycosides can cause fetal harm when administered during pregnancy.
Patient Counselling
Purpose of Therapy
Gentamicin is a powerful intravenous or intramuscular antibiotic used to treat serious bacterial infections. It targets specific types of bacteria that are resistant to other treatments. Because it requires careful dose monitoring through blood tests, it is administered in a hospital or supervised clinical setting. It does not treat viral infections.
How to Take
Gentamicin will be given by a healthcare professional through a vein (slowly over 30 to 60 minutes) or as an injection into a muscle. Blood tests will be taken regularly to check the drug levels in the blood and to monitor kidney function. The typical treatment duration is 7 to 10 days, and it is important to complete the full course as prescribed.
Hearing Changes
Tell patientThis antibiotic can rarely cause hearing problems, including ringing in the ears or difficulty hearing, which may be permanent. Hearing tests may be performed before and during treatment, especially for longer courses.
Call prescriberImmediately if you notice any ringing in your ears, muffled hearing, difficulty understanding speech, or a feeling of fullness in your ears.
Dizziness and Balance
Tell patientGentamicin may affect the balance centres in your inner ear. You may experience dizziness, unsteadiness, or a spinning sensation. These effects can sometimes persist after the drug is stopped.
Call prescriberIf you develop new dizziness, difficulty walking, or a sensation that the room is spinning.
Kidney Function
Tell patientGentamicin can affect the kidneys. Your care team will monitor your kidney function with regular blood and urine tests. Staying well hydrated by drinking adequate fluids helps protect your kidneys during treatment.
Call prescriberIf you notice a significant decrease in urine output, swelling in your legs or feet, or unusually dark urine.
Muscle Weakness or Breathing Difficulty
Tell patientIn rare cases, this drug can cause muscle weakness or breathing difficulty, especially during anaesthesia or if you have a muscle condition such as myasthenia gravis. Inform all healthcare providers that you are receiving gentamicin.
Call prescriberImmediately for any new difficulty breathing, severe muscle weakness, or numbness/tingling.
Pregnancy and Family Planning
Tell patientGentamicin may harm an unborn baby, including causing permanent hearing loss. If you are pregnant, think you may be pregnant, or are planning a pregnancy, inform your doctor before starting treatment.
Call prescriberIf you become pregnant during treatment.
Sources
Regulatory (PI / SmPC)
- Gentamicin Sulfate Injection, USP — Full Prescribing Information (Fresenius Kabi). DailyMed Label Primary FDA label source for all dosing, indications, boxed warnings, adverse reactions, and PK data in this monograph.
- Gentamicin Sulfate Injection, USP — Full Prescribing Information (Hospira/Pfizer). Pfizer Label Alternate brand-reference label providing additional pharmacokinetic and precaution detail.
Key Clinical Trials / Meta-Analyses
- Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39(3):650–655. doi:10.1128/AAC.39.3.650 Landmark observational study validating the safety and efficacy of extended-interval aminoglycoside dosing in a large adult population.
- Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med. 1996;124(8):717–725. doi:10.7326/0003-4819-124-8-199604150-00003 Meta-analysis demonstrating that once-daily dosing is at least as effective and no more toxic than traditional multiple-daily dosing.
- Barza M, Ioannidis JPA, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ. 1996;312(7027):338–345. doi:10.1136/bmj.312.7027.338 Independent meta-analysis confirming similar efficacy and possible reduced nephrotoxicity with single-daily aminoglycoside dosing.
- Lacy MK, Nicolau DP, Nightingale CH, Quintiliani R. The pharmacodynamics of aminoglycosides. Clin Infect Dis. 1998;27(1):23–27. doi:10.1086/514620 Key review establishing the concentration-dependent killing and post-antibiotic effect pharmacodynamic principles underpinning extended-interval dosing.
Guidelines
- Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement from the AHA. Circulation. 2015;132(15):1435–1486. doi:10.1161/CIR.0000000000000296 AHA guideline providing gentamicin synergy dosing recommendations for enterococcal and streptococcal endocarditis.
- Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the SIS and IDSA. Clin Infect Dis. 2010;50(2):133–164. doi:10.1086/649554 SIS/IDSA guideline positioning aminoglycosides (including gentamicin) in combination regimens for complicated intra-abdominal infections.
Mechanistic / Basic Science
- Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155(1):93–99. doi:10.1093/infdis/155.1.93 Established the Cmax:MIC ratio as the primary pharmacodynamic predictor of aminoglycoside clinical efficacy.
- Smith CR, Lipsky JJ, Laskin OL, et al. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med. 1980;302(20):1106–1109. doi:10.1056/NEJM198005153022002 Landmark study establishing nephrotoxicity and ototoxicity incidence rates for aminoglycosides in a controlled clinical setting.
Pharmacokinetics / Special Populations
- Bertino JS Jr, Booker LA, Franck PA, et al. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis. 1993;167(1):173–179. doi:10.1093/infdis/167.1.173 Identified key risk factors for aminoglycoside nephrotoxicity in TDM-guided dosing populations.
- Traynor AM, Nafziger AN, Bertino JS Jr. Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother. 1995;39(2):545–548. doi:10.1128/AAC.39.2.545 Established the 0.4 correction factor for adjusted body weight dosing in obese patients receiving aminoglycosides.
- Touw DJ, Westerman EM, Sprij AJ. Therapeutic drug monitoring of aminoglycosides in neonates. Clin Pharmacokinet. 2009;48(2):71–88. doi:10.2165/0003088-200948020-00001 Comprehensive review of neonatal aminoglycoside pharmacokinetics and TDM strategies informing weight- and age-based dosing recommendations.
- Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother. 1999;43(7):1549–1555. doi:10.1128/AAC.43.7.1549 Prospective study comparing extended-interval vs traditional dosing for nephrotoxicity and ototoxicity outcomes.